Linked Life Data

17185519

Source:http://linkedlifedata.com/resource/pubmed/id/17185519

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-12-22
pubmed:abstractText
This article focuses on pharmacogenetic associations between genetic polymorphism of uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity. Accumulating evidence provides support to the idea that determination of UGT1A1 polymorphisms before irinotecan treatment is clinically useful and important for predicting and avoiding related toxicities. On the basis of these backgrounds, the irinotecan label was updated in 2005 in the United States to provide pharmacogenetic information, and a dose reduction of irinotecan should be considered for patients known to be homozygous for the UGT1A1*28 allele when administered in combination with other agents or a single agent. The irinotecan/UGT1A1 issue and the development of molecular diagnostic testing are now to be translated into clinical practice.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0077-8923
pubmed:author
pubmed:issnType
Print
pubmed:volume
1086
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
223-32
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
pubmed:affiliation
Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. yhasega@med.nagoya-u.ac.jp
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't